NeurAxis Q2: Revenues +46% but operating losses, going-concern and dilution risks remain

NeurAxis, Inc. (NASDAQ: NRXS) - Q2 2025 quick read

Key points & statistics
* Net sales Q2 2025: $894,086 (up 46.2% YoY from $611,500).
* Net sales six months 2025: $1,789,741 (up 42.3% YoY).
* Gross profit Q2 2025: $747,443; gross margin Q2 2025: 83.6% (down from 88.0% in Q2 2024).
* Cost of goods sold Q2 2025: $146,643. Six months COGS: $286,118.
* Operating loss Q2 2025: $(1,717,858); six months operating loss: $(4,012,955).
* Net loss Q2 2025: $(1,690,418); six months net loss: $(3,969,102).
* Net loss available to common stockholders Q2 2025: $(1,897,883); six months: $(4,390,110).
* Basic & diluted loss per share Q2 2025: $(0.22); six months: $(0.56).
* Cash and cash equivalents at June 30, 2025: $5,988,456. Working capital surplus: $4,271,446.
* Stockholders' equity at June 30, 2025: $4,253,294. Shares outstanding: 9,858,716.
* Series B Preferred outstanding (6/30/25): 3,896,907 shares; undeclared cumulative preferred dividends YTD: $421,008.
* Financing activity: May 22, 2025 equity raise - 1,538,461 common shares for $4,999,999; proceeds from exercised warrants: $1,002,991. Offering costs: $490,799.
* Cash flow: Net cash used in operating activities (six months): $(3,071,145). Net cash provided by financing activities: $5,388,019.
* Dilutive potential: Options 1,319,394; RSUs 852,214; Warrants 1,419,524; Series B preferred 3,896,907 - total potential dilutive instruments noted: 7,753,701.
* Legal settlement: $750,000 settlement executed (payable in 12 monthly installments starting Jan 2026); accruals at 6/30/25 - $375,000 (accrued expenses) and $267,540 (other non-current liabilities).
* Material weaknesses in internal control identified; auditors expressed substantial doubt about going concern. Related-party receivables fully reserved: $1,012,800 allowance.

What's happening inside the company
NeurAxis is scaling commercial sales (IB‑STIM + RED launch) and used equity financing in H1 2025 to rebuild cash (net financing proceeds ≈ $5.4M) while operating cash burn remains material (~$3.07M in six months). Management is investing in sales (higher selling expenses) and R&D (RED development and other indications) while resolving legacy legal disputes (settlement of the 2022 suit). Board approved compensation and equity programs (RSUs, ESPP) to retain talent; Series B preferred and multiple warrant/option pools represent meaningful conversion/dilution risk. Controls gaps remain; remediation underway but not complete.

Positive aspects (income statement & finances)
* Revenue growth: net sales rose 46.2% YoY in Q2 and 42.3% for six months - traction at the top line.
* Gross profit up in absolute dollars (Q2 gross profit $747,443) and healthy gross margins (83.6% despite some pressure).
* Net loss narrowed YoY (Q2 net loss down from $(2,917,710) to $(1,690,418)).
* Cash position improved materially to $5.99M following equity raises and warrant exercises - extended near-term runway versus year-end.
* Interest expense declined vs prior year ($13,434 Q2 2025 vs $80,697 Q2 2024), easing financing drag.

Negative aspects (income statement & risks)
* Continued losses and negative operating cash flow: operating loss Q2 $(1.72M); operating cash burn $(3.07M) for six months - profitable operations not yet achieved.
* General & administrative expense remains very large vs revenue: G&A Q2 $2.265M against $0.894M sales (G&A > sales), indicating fixed cost base is high relative to current revenue scale.
* Gross margin deterioration (88.0% → 83.6%) driven by discounting (patient assistance programs) and expired RED inventory - margin volatility risk as product mix shifts.
* Material weaknesses in internal control and a going concern disclosure create execution and reporting risk; remediation incomplete.
* Significant dilution potential: Series B preferred + warrants + options + RSUs represent substantial future share issuance that can dilute common holders and affect EPS recovery.
* Legal and contractual cash obligations (settlement $750k payable starting Jan 2026; Series B cumulative dividends accrued) and related-party allowances ($1,012,800) pressure liquidity and equity.
* Company remains dependent on broader commercial insurance adoption for sustainable revenue growth - a binary operational dependency.

Bottom line / watch items
NeurAxis shows real commercial momentum with meaningful YoY revenue growth and improved cash after an equity raise, but the business is still loss-making with sizable G&A and operating cash burn. Key items to monitor: insurance coverage adoption for IB‑STIM (drives volume and margin), cadence of settlements/payments (750k settlement), completion of internal control remediation and audit/go‑forward opinions, and conversion/dilution from Series B, warrants and RSUs. Near-term runway is improved by the May equity raise, but execution risk and dilution are the principal investor concerns.